Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.

Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ.

Leukemia. 2017 Aug;31(8):1788-1797. doi: 10.1038/leu.2016.373. Epub 2016 Dec 7.

2.

A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1.

Wang H, Yu J, Li L.

Onco Targets Ther. 2015 Oct 23;8:3067-77. doi: 10.2147/OTT.S84888. eCollection 2015.

3.

Genetic and antigenic analysis of mink's immunoglobulin G Fc region.

Jiang L, Li L, Zhao C, Pang XR, Shen Q, Chang WS, Zhai J.

Cent Eur J Immunol. 2014;39(1):36-9. doi: 10.5114/ceji.2014.42120. Epub 2014 Apr 17.

4.

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ.

Oncoimmunology. 2015 Jan 23;4(3):e994446. eCollection 2015 Mar.

5.

Small Circular DNAs in Human Pathology.

Barreto SC, Uppalapati M, Ray A.

Malays J Med Sci. 2014 May;21(3):4-18.

6.

Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus.

Zhang L, Wang Y, Xiao Y, Wang Y, Dong J, Gao K, Gao Y, Wang X, Zhang W, Xu Y, Yan J, Yu J.

PLoS One. 2014 Mar 7;9(3):e90551. doi: 10.1371/journal.pone.0090551. eCollection 2014.

7.

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ.

Blood. 2012 May 3;119(18):4133-41. doi: 10.1182/blood-2011-12-400044. Epub 2012 Feb 21.

8.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.

Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.

9.

Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy.

Meazza R, Azzarone B, Orengo AM, Ferrini S.

J Biomed Biotechnol. 2011;2011:861920. doi: 10.1155/2011/861920. Epub 2011 Jun 13. Review.

10.

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN.

J Exp Med. 2009 Apr 13;206(4):849-66. doi: 10.1084/jem.20081382. Epub 2009 Mar 30.

11.

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB, Krown SE, Livingston PO, Ejadi S, Panageas KS, Engelhorn ME, Terzulli SL, Houghton AN, Wolchok JD.

Mol Ther. 2008 Dec;16(12):2022-9. doi: 10.1038/mt.2008.196. Epub 2008 Sep 16.

12.

Mechanisms of immunization against cancer using chimeric antigens.

Engelhorn ME, Guevara-PatiƱo JA, Merghoub T, Liu C, Ferrone CR, Rizzuto GA, Cymerman DH, Posnett DN, Houghton AN, Wolchok JD.

Mol Ther. 2008 Apr;16(4):773-81. doi: 10.1038/mt.2008.8. Epub 2008 Feb 26.

13.

Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Tsen SW, Paik AH, Hung CF, Wu TC.

Expert Rev Vaccines. 2007 Apr;6(2):227-39. Review.

Supplemental Content

Support Center